| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 06/08/2010 | US7732000 Food intermediate having sequestered phytosteryl esters in a polysaccharide matrix |
| 06/08/2010 | US7731989 Gastric retained gabapentin dosage form |
| 06/08/2010 | US7731986 comprises a sclerosant liquid, e.g. polidocanol solution, and a gas e.g. O2 or CO2; by inter alia causing a localised inflammatory reaction, favor the elimination of varicose veins and other disorders involving venous malformation |
| 06/08/2010 | US7731983 Method and composition for the treatment of scars |
| 06/08/2010 | US7731973 Administering estriol to treat multiple sclerosis, autoimmune diseases, psoriasis, Sjogren's syndrome, encephalomyelitis; inflammatory bowel, Crohn's, Hashimoto's, or Addison's disease; diabetes, myasthenia gravis, lupus, rheumatoid arthritis, polymyositis; immunotherapy; magnetic resonance imaging |
| 06/08/2010 | US7731968 Topical delivery of vaccines |
| 06/08/2010 | US7731955 Using lactoperoxidase composition as a therapeutic treatment for rheumatoid arthritis, sepsis, myleoma and influenza infection |
| 06/08/2010 | US7731954 Wound dressings comprising hydrated hydrogels and enzymes |
| 06/08/2010 | US7731945 Immunotherapy for reversing immune suppression |
| 06/08/2010 | CA2442281C Intravaginal drug delivery devices for the administration of an antimicrobial agent |
| 06/08/2010 | CA2434972C Implantable device containing resorbable matrix material and anti-proliferative drugs for preventing or treating failure of hemodialysis vascular access and other vascular grafts |
| 06/08/2010 | CA2388063C Cytotoxic agents comprising taxanes and their therapeutic use |
| 06/08/2010 | CA2386547C Orally disintegrating composition comprising mirtazapine |
| 06/08/2010 | CA2383233C Surface modified particulate compositions of biologically active substances |
| 06/08/2010 | CA2370019C Transdermal therapeutic system with neutralized acrylic pressure-sensitive adhesives |
| 06/08/2010 | CA2369300C Water-soluble compositions of bioactive lipophilic compounds |
| 06/08/2010 | CA2360590C Solution-based transdermal drug delivery system |
| 06/08/2010 | CA2320390C Pna and dna conjugates and methods for preparation thereof |
| 06/08/2010 | CA2144475C Polyamide-oligonucleotide derivatives, their preparation and use |
| 06/03/2010 | WO2010062996A2 Ribavirin composition |
| 06/03/2010 | WO2010062854A2 Methods and compositions for using bleomycin-derivatized microbubbles |
| 06/03/2010 | WO2010062824A2 Enhanced bioactive formulations of resveratrol |
| 06/03/2010 | WO2010062688A2 Dosage form for insertion into the mouth |
| 06/03/2010 | WO2010062658A1 Compositions and methods of treating demyelinating central nervous system diseases |
| 06/03/2010 | WO2010062570A2 COMPOSITIONS COMPRISING CAPTURE PEPTIDES FOR A β-AMYLOID PEPTIDE |
| 06/03/2010 | WO2010062059A2 Hydrogel type cell delivery vehicle for wound healing, and preparation method thereof |
| 06/03/2010 | WO2010061924A1 Avian influenza vaccine |
| 06/03/2010 | WO2010061921A1 Method for stabilizing l-ascorbic acid, liquid extraction preparation, solid extract, and semi-fluid extract |
| 06/03/2010 | WO2010061919A1 Cytotoxic t cell epitope peptide for sars coronavirus, and use thereof |
| 06/03/2010 | WO2010061880A1 Vesicle preparation |
| 06/03/2010 | WO2010061846A1 Orally rapidly disintegrating tablet, and process for producing same |
| 06/03/2010 | WO2010061474A1 Connecting magnetic element, connecting magnetic element manufacturing method, connecting magnetic element injecting device, connecting magnetic element injection control system, magnetic field control device, and connecting magnetic element injection control method |
| 06/03/2010 | WO2010061453A1 Chitin emulsion and method for producing the same |
| 06/03/2010 | WO2010061193A2 Compositions with reduced dimer formation |
| 06/03/2010 | WO2010060989A1 Solution of lipophilic substances, especially medicinal solutions |
| 06/03/2010 | WO2010060901A1 Peptides for treatment of obesity |
| 06/03/2010 | WO2010060798A1 Pharmaceutical formulation comprising diclofenac and a hydroxy fatty acid polyoxyalkylene ester |
| 06/03/2010 | WO2010060667A1 Pharmaceutical compositions suitable for oral administration of derivatized insulin peptides |
| 06/03/2010 | WO2010060529A1 Microparticles comprising a salt of 8-hydroxy-2- [ [ ( ir) -2- (4-methoxyphenyl) -l-methylethyl] aminol ethyll -2 (ih) -quinolin one |
| 06/03/2010 | WO2010060260A1 Novel multi-arm polyethylene glycol, preparation method and uses thereof |
| 06/03/2010 | WO2010060200A1 Bacteriophage compositions for treatment of bacterial infections |
| 06/03/2010 | WO2010033220A3 Modified therapeutics peptides, methods of their preparation and use |
| 06/03/2010 | WO2010033219A3 Protease inhibitors having enhanced features |
| 06/03/2010 | WO2010033204A3 Polymer conjugates of c-peptides |
| 06/03/2010 | WO2010032248A8 Multifunctional albumin conjugates |
| 06/03/2010 | WO2010030598A3 Pharmaceutical formulations comprising pemetrexed |
| 06/03/2010 | WO2010027498A3 Compositions and methods for inducing satiety and treating non-insulin dependent diabetes emillitus, pre-diabetic symptoms, insulin resistance and related disease states and conditions |
| 06/03/2010 | WO2009100351A3 Delivery of rnai constructs to oligodendrocytes |
| 06/03/2010 | WO2009087632A3 Emulsified wax compositions and uses thereof |
| 06/03/2010 | WO2009080764A3 Oral or nasal administration of compounds comprising amino acid sequences |
| 06/03/2010 | US20100137512 Polyethylene glycol/polycation block copolymers |
| 06/03/2010 | US20100137456 Polysaccharides functionalized by tryptophan derivatives |
| 06/03/2010 | US20100137455 N-vinylcaprolactam-based copolymers and the use thereof as solubilizers |
| 06/03/2010 | US20100137454 Silicone Polymer Emulsions |
| 06/03/2010 | US20100137453 Polyurea Product as Thixotropic Rheology Modifying Agent |
| 06/03/2010 | US20100137452 Aqueous compositions having protected hydrophilic actives |
| 06/03/2010 | US20100137389 Topical formulation |
| 06/03/2010 | US20100137369 Flowable pharmaceutical depot |
| 06/03/2010 | US20100137304 Novel crystalline forms of the anti-cancer compound zd1839 |
| 06/03/2010 | US20100137271 Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs |
| 06/03/2010 | US20100137198 Pharmaceutical composition for topical application |
| 06/03/2010 | US20100136648 Expansion Moulding of Shape Memory Polymers |
| 06/03/2010 | US20100136117 Hydroxyapatite tissue filler and its preparation and use |
| 06/03/2010 | US20100136105 Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs |
| 06/03/2010 | US20100136084 Responsive polymeric system |
| 06/03/2010 | US20100136066 Novel Inverse Latex Of Anionic Polyelectrolytes In Silicones Oils; Cosmetic Use |
| 06/03/2010 | US20100136043 Composition comprising immunogenic microparticles |
| 06/03/2010 | US20100136033 METHODS OF TREATMENT USING ANTI-ErbB ANTIBODY-MAYTANSINOID CONJUGATES |
| 06/03/2010 | US20100135936 Delivery of hydrophobic benefit agents from bodywashes and the like onto a keratinous substrate |
| 06/03/2010 | US20100135935 Composition using cross-linked hyaluronic acid for topical cosmetic and therapeutic applications |
| 06/03/2010 | US20100135909 Dendrimers and methods of making and using thereof |
| 06/03/2010 | US20100135901 Combination therapy |
| 06/03/2010 | CA2748344A1 Enhanced bioactive formulations of resveratrol |
| 06/03/2010 | CA2746205A1 Dosage form for insertion into the mouth |
| 06/03/2010 | CA2744909A1 Bacteriophage compositions for treatment of bacterial infections |
| 06/03/2010 | CA2744587A1 Compositions with reduced dimer formation |
| 06/03/2010 | CA2743243A1 Solution of lipophilic substances, especially medicinal solutions |
| 06/03/2010 | CA2742791A1 Stable antibody compositions and methods for stabilizing same |
| 06/03/2010 | CA2742645A1 Pharmaceutical formulation comprising diclofenac and a hydroxy fatty acid polyoxyalkylene ester |
| 06/02/2010 | EP2191890A1 Process for producing fine particles and the fine particles |
| 06/02/2010 | EP2191849A1 Drug for suppressing pathogen occurring<i>in vivo</i> |
| 06/02/2010 | EP2191848A1 Sustained release preparation and process for production thereof |
| 06/02/2010 | EP2191847A1 Method for preparing compositions comprising a protein, water and glycerol |
| 06/02/2010 | EP2191839A2 Immunogenic LHRH compositions and methods relating thereto |
| 06/02/2010 | EP2191833A1 Transdermally absorbable preparation |
| 06/02/2010 | EP2191830A1 Solid preparation comprising npyy5 receptor antagonist |
| 06/02/2010 | EP2191828A1 Antifungal pharmaceutical composition |
| 06/02/2010 | EP2191827A1 Antifungal composition |
| 06/02/2010 | EP2191826A1 Pharmaceutical composition |
| 06/02/2010 | EP2191825A1 Agent for fungal dermatitis |
| 06/02/2010 | EP2191821A1 Microparticles comprising a salt of 8-hydroxy-2-[[(1R)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]-2(1H)-quinolinone having improved adhesion properties for dry powder inhalation |
| 06/02/2010 | EP2191810A1 Cosmetic auxiliary patch material and method of cosmetizing therewith |
| 06/02/2010 | EP2190931A2 Optical imaging agents |
| 06/02/2010 | EP2190930A2 Peptide imaging agents |
| 06/02/2010 | EP2190880A1 Cytotoxicity mediation of cells evidencing surface expression of cd9 |
| 06/02/2010 | EP2190860A1 Blood coagulation factor inhibitors |
| 06/02/2010 | EP2190857A1 Glycoproteins and glycosylated cells and a method for the preparation of the same |
| 06/02/2010 | EP2190482A2 Targeted block copolymer micelles |
| 06/02/2010 | EP2190436A2 Sulfasalazine formulations in a biodegradable polymer carrier |
| 06/02/2010 | EP2190412A2 Liposome formulations of boronic acid compounds |